How is Biogen (BIIB) doing?

Biogen is a company in the drug manufacturers, general industry, based in Cambridge, MA, worth $33.3B. Here is how its shares and business compare with the rest of the market, and where it shows up on our dashboards.

Updated Oct 9, 2026

P3 score

Middling

Biogen shares are up 50% over the past year, 29 points ahead of the S&P 500. Its type is Rolling Over. Among large US stocks and funds it ranks in the 89th percentile on market beat, the 71st on staying power and the 8th on business growth. It appears on 8 of our dashboards.

$225.71+50% in a yearWorth $33.3B

Compare with VRTX · REGN · AMGN · LLY · ALNY · MRNA

Financials, earnings and news on Stox ›

Past year

The past year

Price against the S&P 500, each set to $100 a year ago. Score is its weekly rank against the market. Select a tile for that score month by month.

BIIB against the S&P 500, past year

$100 a year ago. Biogen +50%, the S&P 500 +16%.

BIIBS&P 500

What kind of stock is it?

Its type on Stox Atlas, from its four scores: beating or lagging the market, a steady or erratic rank, a growing or slowing business, and whether buyers or sellers lead.

Rolling Over

BeatingSteadySlowingSold

A steady winner whose business growth trails most, and where selling has taken over.

NovDecJanFebMarAprMayJunJulAugSepNow

Rolling Over this month; Faith Trade before that.

Also Rolling Over (37 in all): CORT · JHX · BRKR · ROIV · GL · AMKR

EmbracedToppingAccumulatingRejectedStable rankBellwetherDistribution TopCoiled SpringWallflowerHolding rankFaith TradeRolling OverBottom FishedSleepy StapleUnsteady rankHot HandChurning WinnerTurning UpShow-Me GrowerBouncy rankSpeculative PopExhausted RallyFalling KnifeBroken Year

How is it doing against its group?

Its group is Health care, 86 large US stocks and funds whose prices tend to move together. Tools, biotech and large-cap pharma — defensive growth.

BIIB, past year+50%14 of 86 in the group

Rest of the group+20%equal-weighted

S&P 500+16%past year

Biogen is +50% over the past year, against +20% for the rest of the group and +16% for the S&P 500. It ranks 14th of 86 in Health care.

BIIBRest of the group

Best in the groupRVMD Revolution Medicines+297%ILMN Illumina+184%NTRA Natera+133%

Worst in the groupPODD Insulet−57%BSX Boston Scientific−56%RARE Ultragenyx−50%

Its closest rivalsVRTX Vertex Pharmaceuticals+21%REGN Regeneron Pharmaceuticals+32%AMGN Amgen+41%LLY Lilly (Eli)+39%ALNY Alnylam Pharmaceuticals−48%

Health care on Stox ›

How much does it move?

Its typical daily move, against its own past year, the market and other large stocks. Swings describe risk, not direction.

About usual Biogen typically moves 2.7% in a day, about usual for it, and it swings less than 53% of large US stocks.

Typical day2.7%about $6.05 a share

Its usual3.0%about usual, 0.9× its year’s average

Against the S&P 5002.7×the index’s typical day is 1.1%

Unusual day±5.4%twice its typical day

Deepest fall, past year−14%now 1% below its high

In the S&P’s down weeks109%of the index’s fall, three years; beta 0.6

Typical daily move (ATR)Its year’s average 3.03%

BIIB on our dashboards

Every question where Biogen appears, in the order of the home page, with its reading and place in that table. Select a question to open it with BIIB highlighted. Select a column to sort.

Question	Reading	Place	Details
What moved today, and why? What’s leading	91Unusual	22 of 30	Today +3.3% · × normal day 1.2×
Which companies do analysts expect to grow fastest? Earnings	93Fast	37 of 60	EPS growth +33% · This year 12.42 · Next year 16.55
Which stocks keep winning? Leading stocks	9432 of 52 wks	30 of 60	vs S&P, 1Y +34 pts · Rank steadiness 71 · P3 score 37
Which companies are built to last? Business quality	63Solid	50 of 60	Steady margins 85 · Reliable cash 57 · Balance sheet 46
Whose cash flow backs up their earnings? Business quality	93Backed	26 of 60	3 years 179% · Last year 300% · Free cash flow $3.0B
Which companies invest the most in research? Business quality	83Heavy	34 of 60	R&D / revenue 19.6% · R&D a year $1.9B · R&D, 1Y −20%
Which stocks are cheap for their growth? Value	100Cheap	17 of 60	PEG 0.55 · Forward P/E 18.3× · Expected EPS growth +33%
Which stocks are cheapest on cash flow? Value	91Cheap	57 of 60	Cash yield 8.8% · Price / FCF 11.4× · Cash margin 30%

Go deeper on Stox

BIIB’s full profile: financial statements, earnings and analysts’ estimates, valuation against its sector, recent news with a summary, and its scores in detail.

Open BIIB on Stox ›All 16 types on Atlas ›Its group on Stox ›

How to read this page

How it’s measured. Scores from Stox rank the stock against about 1,200 S&P 500, Nasdaq-100 and Russell 1000 stocks and popular funds, where 100 is best; market beat and staying power use prices, business growth uses revenue, margins and cash flow. Readings on other dashboards come from this site’s pages.

Sources. Daily prices and company financial statements from Financial Modeling Prep; scores and co-movement groups from Stox.

Scores are percentiles: 80 means the stock ranks above 80% of the others on that measure. They describe the recent past and are not advice or a forecast.

Its type follows Stox Atlas: each of the four scores is split at 50. “Steady” means its rank has held, high or low, so it says nothing on its own about direction.

Its group is the cluster of large US stocks whose prices have moved together over five years, with the market’s own moves taken out. The typical daily move is the average true range over 14 days, a measure of how far the price travels in a day including overnight gaps.

For financial statements, earnings and news, see BIIB’s full profile on Stox.

This page is information, not investment advice. About our data and methods ›

Full profile on Stox ›Health care stocks ›VRTX · Vertex Pharmaceuticals ›REGN · Regeneron Pharmaceuticals ›AMGN · Amgen ›LLY · Lilly (Eli) ›